by Jason Heaviland | Apr 20, 2026 | Uncategorized
Alzheimer’s as a System-Level Disorder via Multi-Omics Alzheimer’s disease is not driven by a single pathway, molecule or mutation. Instead, it reflects a system-level breakdown across metabolism, protein regulation and cellular signaling. Yet most studies still...
by Jason Heaviland | Apr 14, 2026 | Uncategorized
In exposomics, there are two fundamentally different ways to explore the chemical world influencing human health and choosing the right one can make or break your study. Think of it like this: Are you searching for something specific or are you trying to discover what...
by Jason Heaviland | Apr 10, 2026 | Uncategorized
Terms like “comprehensive coverage” and “untargeted detection” are widely used in metabolomics, but they are rarely evaluated in controlled comparisons. Panome Bio conducted a head-to-head study against a widely used legacy platform using identical samples,...
by Jason Heaviland | Mar 31, 2026 | Uncategorized
Researchers run experiments, send samples, and receive results that appear complete. However, a significant portion of the metabolome may never be captured in the final dataset. Not due to sample quality or preparation, but because many metabolomics platforms are...
by Jason Heaviland | Feb 27, 2026 | Uncategorized
For 20 years, genomics has promised precision medicine. And it delivered. For rare diseases and select cancers. But for most chronic conditions?
Genetics explains only a fraction of risk. Type 2 diabetes. Alzheimer’s disease. Autoimmune disorders. Metabolic syndrome....
